



ASX ANNOUNCEMENT

19 August 2008

VitroGro® Clinical Trial: Share Purchase Plan Extended

Biomedical company, **Tissue Therapies Limited (ASX: TIS)** announced today further information (attached) about the human trial of VitroGro® that started in Perth, Western Australian on Monday 11 August.

The attached update has been mailed to all share holders today. To provide share holders with time to receive this mail out, review the contents and to make a considered decision on participation in the Share Purchase Plan offer, the Board of Tissue Therapies has decided to extend the closing date from Monday 25 August to Friday 5 September. Closing time remains 4:00 pm Brisbane time.

A further announcement will be made defining the revised offer timetable, including the anticipated quotation date of the new shares issued under the Share Purchase Plan.

Further information: Dr Steven Mercer
 CEO, Tissue Therapies Limited
 Telephone: 07 3839 9938

 Email: s.mercer@tissuetherapies.com

About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue repair and various cell culture applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a technology developed by tissue engineering experts at the Institute for Health and Biomedical Innovation at QUT for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, stem cell therapies and other cell culture uses.

Based on its VitroGro® technology, Tissue Therapies is developing more effective medical treatments for wound healing including chronic ulcers and burns,

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: www.tissuetherapies.com

